Fundraising Fox

Artios Pharma

7 known investors

artios.com β†—

Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.

BiotechHealthtech

Investors Β· 7

Andera PartnersParis
M VenturesLos Angeles Β· $10.8M
Novartis Venture FundBasel Β· $5M – $25M
Pfizer Venture Investments$5M – $20M
RA CapitalBoston
Sofinnova PartnersParis Β· $540K – $27M
SV Health InvestorsBoston Β· $1M – $20M

Frequently asked questions

What does Artios Pharma do?
Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.
Who are Artios Pharma's investors?
Artios Pharma's investors include Andera Partners, M Ventures, Novartis Venture Fund, Pfizer Venture Investments, RA Capital, Sofinnova Partners, SV Health Investors.